Search Results - "WOLBINK, G. J."

The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region by van Schie, K A, Hart, M H, de Groot, E R, Kruithof, S, Aarden, L A, Wolbink, G J, Rispens, T

“…In a subset of patients, anti tumour necrosis factor (TNF) therapeutic antibodies are immunogenic, resulting in the formation of antidrug antibodies (ADAs)…”
Get more information

Spinning straw into gold: description of a disruptive rheumatology research platform inspired by the COVID-19 pandemic by Boekel, L, Hooijberg, F, Vogelzang, E H, Klarenbeek, P L, Bos, W H, Tas, S W, Wolbink, G J

“…Clinical research projects often use traditional methods in which data collection and signing informed consent forms rely on patients' visits to the research…”
Get full text

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease by WEST, R. L., ZELINKOVA, Z., WOLBINK, G. J., KUIPERS, E. J., STOKKERS, P. C. F., VAN DER WOUDE, C. J.

“…Summary Background  Adalimumab is an effective treatment in patients with Crohn’s disease; as it is a humanized anti‐tumour necrosis factor monoclonal…”
Get full text

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients by Jamnitski, A, Krieckaert, C L, Nurmohamed, M T, Hart, M H, Dijkmans, B A, Aarden, L, Voskuyl, A E, Wolbink, G J

“…To investigate the relationship between serum etanercept levels and clinical response. In 292 etanercept-treated patients with rheumatoid arthritis clinical…”
Get more information

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study by Bartelds, G M, Wijbrandts, C A, Nurmohamed, M T, Stapel, S, Lems, W F, Aarden, L, Dijkmans, B A C, Tak, P P, Wolbink, G J

“…To investigate how antibodies against anti-tumour necrosis factor (anti-TNF) agents influence response after switching from infliximab to adalimumab in…”
Get more information

Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study by Bos, W H, Wolbink, G J, Boers, M, Tijhuis, G J, de Vries, N, van der Horst-Bruinsma, I E, Tak, P P, van de Stadt, R J, van der Laken, C J, Dijkmans, B A C, van Schaardenburg, D

“…Anti-citrullinated protein antibodies (ACPA) are associated with increased risk for rheumatoid arthritis. To investigate the effect of the presence and levels…”
Get more information

A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides by Bossini-Castillo, L, de Kovel, C, Kallberg, H, van 't Slot, R, Italiaander, A, Coenen, M, Tak, P P, Posthumus, M D, Wijmenga, C, Huizinga, T, van der Helm-van Mil, A H M, Stoeken-Rijsbergen, G, Rodriguez-Rodriguez, Luis, Balsa, Alejandro, González-Álvaro, Isidoro, González-Gay, Miguel Ángel, Gómez-Vaquero, Carmen, Franke, B, Vermeulen, S, van der Horst-Bruinsma, Ie, Dijkmans, B A C, Wolbink, G J, Ophoff, R A, Maehlen, M T, van Riel, P, Merriman, M, Klareskog, L, Lie, B A, Merriman, T, Crusius, J B A, Brouwer, E, Martin, J, de Vries, N, Toes, R, Padyukov, L, Koeleman, B P C

“…Rheumatoid arthritis (RA) patients can be classified based on presence or absence of anticitrullinated peptide antibodies (ACPA) in their serum. This…”
Get more information

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis by Wolbink, G J, Voskuyl, A E, Lems, W F, de Groot, E, Nurmohamed, M T, Tak, P P, Dijkmans, B A C, Aarden, L

“…Objective: To investigate the relationship between serum trough infliximab levels and clinical response to infliximab treatment in patients with rheumatoid…”
Get full text

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis by de Vries, M K, van der Horst-Bruinsma, I E, Nurmohamed, M T, Aarden, L A, Stapel, S O, Peters, M J L, van Denderen, J C, Dijkmans, B A C, Wolbink, G J

“…Immunogenicity, specifically the onset of antibodies against tumour necrosis factor (TNF) blocking agents, seems to play an important role in non-response to…”
Get more information

Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis by Thurlings, R M, Teng, O, Vos, K, Gerlag, D M, Aarden, L, Stapel, S O, van Laar, J M, Tak, P P, Wolbink, G J

“…To analyse whether persistence of synovial B lineage cells and lack of clinical response to rituximab treatment in patients with rheumatoid arthritis (RA) are…”
Get more information

Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis by van Kuijk, A W R, de Groot, M, Stapel, S O, Dijkmans, B A C, Wolbink, G J, Tak, P P

Get more information

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium by Wijbrandts, C A, Dijkgraaf, M G W, Kraan, M C, Vinkenoog, M, Smeets, T J, Dinant, H, Vos, K, Lems, W F, Wolbink, G J, Sijpkens, D, Dijkmans, B A C, Tak, P P

“…To determine whether the heterogeneous clinical response to tumour necrosis factor (TNF)alpha blocking therapy in rheumatoid arthritis (RA) can be predicted by…”
Get more information

Elevated Fab glycosylation of anti-hinge antibodies by Koers, J, Derksen, NIL, Falkenburg, WJJ, Ooijevaar-de Heer, P, Nurmohamed, MT, Wolbink, GJ, Rispens, T

“…Rheumatoid arthritis (RA) is characterized by systemic inflammation and the presence of anti-citrullinated protein antibodies (ACPAs), which contain remarkably…”
Get full text

Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial by Ruwaard, J, L' Ami, MJ, Kneepkens, EL, Krieckaert, CLM, Nurmohamed, MT, Hooijberg, F, van Kuijk, AWR, van Denderen, JC, Burgemeister, L, Rispens, T, Boers, M, Wolbink, GJ

“…The majority of patients with a rheumatic disease treated with etanercept may be overexposed. Data regarding etanercept tapering are scarce, particularly in…”
Get full text

Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation by de Vries, M K, Brouwer, E, van der Horst-Bruinsma, I E, Spoorenberg, A, van Denderen, J C, Jamnitski, A, Nurmohamed, M T, Dijkmans, B A C, Aarden, L A, Wolbink, G J

Get more information

Serum drug concentrations to optimize switching from adalimumab to etanercept in rheumatoid arthritis by l' Ami, MJ, Ruwaard, J, Krieckaert, CLM, Nurmohamed, MT, van Vollenhoven, RF, Rispens, T, Wolbink, GJ

“…Objectives: Inadequate response to adalimumab can be caused by insufficient blockade of the target tumour necrosis factor (TNF) at low serum concentrations. In…”
Get full text

Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis by Peters, M J L, Vis, M, van Halm, V P, Wolbink, G J, Voskuyl, A E, Lems, W F, Dijkmans, B A C, Twisk, J W R, de Koning, M H M T, van de Stadt, R J, Nurmohamed, M T

“…Objective: To evaluate the effects of infliximab and corticosteroid treatment on the lipid profile in patients with active rheumatoid arthritis (RA). Methods:…”
Get full text

Circulating microparticles remain associated with complement activation despite intensive anti-inflammatory therapy in early rheumatoid arthritis by van Eijk, I C, Tushuizen, M E, Sturk, A, Dijkmans, B A C, Boers, M, Voskuyl, A E, Diamant, M, Wolbink, G J, Nieuwland, R, Nurmohamed, M T

“…Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterised by synovitis and joint destruction. The pathogenesis of RA is not clear, but…”
Get more information

The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis by ARENDS, S, LEBBINK, H. R, WOLBINK, G. J, BROUWER, E, SPOORENBERG, A, BUNGENER, L. B, ROOZENDAAL, C, VAN DER VEER, E, HOUTMAN, P. M, GRIEP, E. N, LIMBURG, P. C, KALLENBERG, C. G. M

“…To investigate the influence of antibody formation to TNF-α blocking agents on the clinical response in AS patients treated with infliximab (IFX), etanercept…”
Get full text

Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study by van den Bemt, B J F, den Broeder, A A, Snijders, G F, Hekster, Y A, van Riel, P L C M, Benraad, B, Wolbink, G J, van den Hoogen, F H J

“…In clinical trials only a small subset of patients with rheumatoid arthritis (RA) benefits from higher than standard dose of infliximab (>3 mg/kg/8 weeks)…”
Get more information